LT3124610T - Hbv gydymas - Google Patents

Hbv gydymas

Info

Publication number
LT3124610T
LT3124610T LTEP16188642.9T LT16188642T LT3124610T LT 3124610 T LT3124610 T LT 3124610T LT 16188642 T LT16188642 T LT 16188642T LT 3124610 T LT3124610 T LT 3124610T
Authority
LT
Lithuania
Prior art keywords
hbv treatment
hbv
treatment
Prior art date
Application number
LTEP16188642.9T
Other languages
English (en)
Inventor
Michael Wayne Graham
Peter French
York Yuan Yuan Zhu
Yixiang Lu
Tiejun Li
Yuncheng Sun
Xiaojun Tang
Li SHAN
Original Assignee
Benitec Biopharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201010522003.3A external-priority patent/CN101979557B/zh
Priority claimed from CN201010521972.7A external-priority patent/CN102021170B/zh
Priority claimed from CN201010521975.0A external-priority patent/CN101979555B/zh
Priority claimed from CN201010521948.3A external-priority patent/CN101979553B/zh
Priority claimed from CN201010522005.2A external-priority patent/CN101979558B/zh
Priority claimed from CN201010521990.5A external-priority patent/CN101979556B/zh
Priority claimed from CN201010521962.3A external-priority patent/CN101979554B/zh
Priority claimed from PCT/CN2011/071107 external-priority patent/WO2012109798A1/en
Application filed by Benitec Biopharma Limited filed Critical Benitec Biopharma Limited
Publication of LT3124610T publication Critical patent/LT3124610T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of Eletrric Generators (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
LTEP16188642.9T 2010-10-28 2011-10-27 Hbv gydymas LT3124610T (lt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN201010522003.3A CN101979557B (zh) 2010-10-28 2010-10-28 一种siRNA分子及其在抗病毒药物中的应用
CN201010521972.7A CN102021170B (zh) 2010-10-28 2010-10-28 一种干扰乙型肝炎病毒基因的siRNA分子及其应用
CN201010521975.0A CN101979555B (zh) 2010-10-28 2010-10-28 一种小干扰rna分子及其应用
CN201010521948.3A CN101979553B (zh) 2010-10-28 2010-10-28 一种干扰HBV基因的siRNA分子及其抗病毒应用
CN201010522005.2A CN101979558B (zh) 2010-10-28 2010-10-28 一种靶向乙型肝炎病毒基因的siRNA分子及其应用
CN201010521990.5A CN101979556B (zh) 2010-10-28 2010-10-28 一种siRNA靶向分子及其应用
CN201010521962.3A CN101979554B (zh) 2010-10-28 2010-10-28 一种干扰HBV基因的siRNA分子及其应用
PCT/CN2011/071107 WO2012109798A1 (en) 2011-02-18 2011-02-18 Hbv treatment

Publications (1)

Publication Number Publication Date
LT3124610T true LT3124610T (lt) 2019-08-12

Family

ID=45993174

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16188642.9T LT3124610T (lt) 2010-10-28 2011-10-27 Hbv gydymas

Country Status (21)

Country Link
US (2) US9080174B2 (lt)
EP (2) EP3124610B1 (lt)
KR (2) KR20180110186A (lt)
CN (1) CN103370415B (lt)
AU (1) AU2011320437B2 (lt)
BR (1) BR112013010525A2 (lt)
CA (1) CA2853613C (lt)
CY (1) CY1121894T1 (lt)
DK (1) DK3124610T3 (lt)
ES (1) ES2730393T3 (lt)
HR (1) HRP20190995T1 (lt)
HU (1) HUE044426T2 (lt)
LT (1) LT3124610T (lt)
PL (1) PL3124610T3 (lt)
PT (1) PT3124610T (lt)
RS (1) RS58982B1 (lt)
RU (1) RU2620966C2 (lt)
SI (1) SI3124610T1 (lt)
SM (1) SMT201900317T1 (lt)
TR (1) TR201908127T4 (lt)
WO (1) WO2012055362A1 (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12019502377A1 (en) 2011-04-21 2022-11-14 Isis Pharmaceuticals Inc Modulation of hepatitis b virus (hbv) expression
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
CN105002214B (zh) * 2015-04-08 2018-07-17 许中伟 用于载体表达的复合多联gRNA和RNAi的表达框架
CN107683336A (zh) * 2015-05-06 2018-02-09 贝尼泰克生物制药有限公司 用于治疗乙型肝炎病毒(hbv)感染的试剂及其用途
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
KR20250065735A (ko) 2016-03-14 2025-05-13 에프. 호프만-라 로슈 아게 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
US11535851B2 (en) 2016-05-05 2022-12-27 Benitec IP Holdings Inc. Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
CN109414448B (zh) 2016-06-17 2021-10-26 豪夫迈·罗氏有限公司 用于减少PAPD5或PAPD7 mRNA治疗乙型肝炎感染的核酸分子
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
CN108929870B (zh) * 2017-05-19 2020-01-24 百奥迈科生物技术有限公司 抑制HBV的siRNA分子及其应用
UA126931C2 (uk) 2017-10-16 2023-02-22 Ф. Хоффманн-Ля Рош Аг МОЛЕКУЛИ НУКЛЕЇНОВИХ КИСЛОТ ДЛЯ ЗМЕНШЕННЯ РІВНЯ мРНК PAPD5 І PAPD7 ДЛЯ ЛІКУВАННЯ ІНФЕКЦІЙНОГО ГЕПАТИТУ B
MA52661A (fr) 2018-04-05 2021-02-17 Centre Leon Berard Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b
SG11202012759XA (en) 2018-07-03 2021-01-28 Hoffmann La Roche Oligonucleotides for modulating tau expression
EP4512407A3 (en) 2018-07-13 2025-09-24 F. Hoffmann-La Roche AG Oligonucleotides for modulating rtel1 expression
CN114901821A (zh) 2019-12-19 2022-08-12 豪夫迈·罗氏有限公司 Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
JP2023506550A (ja) 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染症を処置するためのｓｂｄｓ阻害剤の使用
CN115516091A (zh) 2019-12-19 2022-12-23 豪夫迈·罗氏有限公司 Cops3抑制剂用于治疗乙型肝炎病毒感染的用途
JP2023506954A (ja) 2019-12-19 2023-02-20 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用
JP2023538630A (ja) 2020-08-21 2023-09-08 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
TW202246500A (zh) 2021-02-02 2022-12-01 瑞士商赫孚孟拉羅股份公司 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
EP4448106A1 (en) 2021-12-17 2024-10-23 Hoffmann-La Roche Inc. Combination of oligonucleotides for modulating rtel1 and fubp1
US20240309383A1 (en) * 2023-02-24 2024-09-19 Suzhou Sanegene Bio Inc. Small interfering rna targeting hbv and uses thereof
CN118995698A (zh) * 2023-05-17 2024-11-22 南京晖丽生物科技有限公司 小核酸在制备治疗猫传染性腹膜炎药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
WO1999049029A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
AU2002326906C1 (en) 2001-09-13 2009-01-29 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
WO2004020605A2 (en) 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
CA2527907A1 (en) 2003-06-03 2004-12-09 Benitec Australia Limited Double-stranded hairpin rnas for rnai
AU2005222084B2 (en) 2004-03-05 2010-04-22 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of RNAI agents
CA2596711C (en) 2005-02-03 2015-12-15 Benitec, Inc. Rnai expression constructs
US8008468B2 (en) * 2005-02-16 2011-08-30 Benitec, Inc. RNAi expression constructs with liver-specific enhancer/promoter
AR057252A1 (es) * 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
WO2007120533A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Minigene expression cassette
CN101684478B (zh) * 2009-06-26 2012-02-29 武汉大学 一种串联表达小干扰rna重组慢病毒载体的构建方法
CN101979556B (zh) 2010-10-28 2015-01-21 百奥迈科生物技术有限公司 一种siRNA靶向分子及其应用

Also Published As

Publication number Publication date
US20130296401A1 (en) 2013-11-07
AU2011320437B2 (en) 2017-03-16
EP2633051B1 (en) 2016-09-14
PT3124610T (pt) 2019-06-14
EP3124610B1 (en) 2019-03-06
US9410154B2 (en) 2016-08-09
WO2012055362A1 (en) 2012-05-03
KR20180110186A (ko) 2018-10-08
PL3124610T3 (pl) 2019-09-30
US9080174B2 (en) 2015-07-14
ES2730393T3 (es) 2019-11-11
EP3124610A1 (en) 2017-02-01
CY1121894T1 (el) 2020-10-14
TR201908127T4 (tr) 2019-06-21
RU2013124422A (ru) 2014-12-10
KR101903778B1 (ko) 2018-10-04
CN103370415A (zh) 2013-10-23
BR112013010525A2 (pt) 2016-08-02
SI3124610T1 (sl) 2019-08-30
CA2853613C (en) 2020-03-24
CA2853613A1 (en) 2012-05-03
EP2633051A1 (en) 2013-09-04
CN103370415B (zh) 2017-05-31
DK3124610T3 (da) 2019-06-11
HRP20190995T1 (hr) 2019-08-09
RU2620966C2 (ru) 2017-05-30
EP2633051A4 (en) 2014-04-23
HUE044426T2 (hu) 2019-10-28
SMT201900317T1 (it) 2019-09-09
US20150344885A1 (en) 2015-12-03
AU2011320437A1 (en) 2013-06-13
KR20140071949A (ko) 2014-06-12
RS58982B1 (sr) 2019-08-30

Similar Documents

Publication Publication Date Title
HUE044426T2 (hu) HBV kezelés
PL2652193T3 (pl) Obróbka
GB2478797B (en) Waste treatment
PH12013500022A1 (en) Surface treatment
EP2521569A4 (en) COMBINATION THERAPY WITH VB-201
EP2521550A4 (en) METHOD OF TREATMENT
GB0900599D0 (en) Treatment
GB201013573D0 (en) Treatment
EP2560679A4 (en) TREATMENT OF ECZEMA
GB0913968D0 (en) Treatment
ZA201308117B (en) Avian-based treatment
GB201001521D0 (en) Treatment
GB201014097D0 (en) Treatment
GB201102283D0 (en) Treatment
GB201021319D0 (en) Treatment
GB2483219B (en) Surface Treatment
GB201014736D0 (en) Treatment of hepatitis C
GB201102274D0 (en) Treatment
GB201102265D0 (en) Treatment
GB201102263D0 (en) Treatment
GB201102267D0 (en) Treatment
GB201102277D0 (en) Treatment
GB201102282D0 (en) Treatment
GB201102266D0 (en) Treatment
GB201102284D0 (en) Treatment